Area of research
Hematology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Hematopoietic Stem Cell Transplantation, Lymphoma Diagnosis and Treatment, and Acute Myeloid Leukemia Research.
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma
Incidence and Outcomes of Adenovirus Infections after Allogeneic Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis
Outcomes of Terminal Complement Blockade in Adults with High-Risk Transplant-Associated Thrombotic Microangiopathy: A Comparative Analysis
Antibody Titers of Vaccine-Preventable Pathogens at 1 Year Post CD19 CAR-T Cell Therapy
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact.
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma.
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort.
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.
Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma.
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines.
Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation.
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas
Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy.
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.